Zenke Yoshitaka, Hakozaki Taiki, Nakahara Yoshiro, Horinouchi Hidehito, Ohe Yuichiro
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Jpn J Clin Oncol. 2022 Oct 6;52(10):1082-1088. doi: 10.1093/jjco/hyac135.
Lung cancer is the most common cause of cancer-related death globally. In addition, its incidence increases with age, with approximately half of all cases diagnosed in patients aged ≥70. Molecular targeted therapies and immunotherapies for advanced non-small-cell lung cancer have markedly improved outcomes over the past two decades. Despite the high incidence of lung cancer in older people, most trials excluded such patients from enrollment. Therefore, the optimal treatment strategies for older patients remain unclear. The present review summarizes the published literature and provides guidance on the treatment of older patients with lung cancer within three broad stages: (i) early-stage lung cancer, (ii) locally advanced lung cancer and (iii) metastatic lung cancer. We also discuss the use of the latest evidence for older patients.
肺癌是全球癌症相关死亡的最常见原因。此外，其发病率随年龄增长而增加，所有病例中约有一半是在70岁及以上的患者中诊断出来的。在过去二十年中，晚期非小细胞肺癌的分子靶向治疗和免疫治疗显著改善了治疗效果。尽管老年人肺癌发病率很高，但大多数试验都将这类患者排除在入组之外。因此，老年患者的最佳治疗策略仍不明确。本综述总结了已发表的文献，并在三个广泛阶段为老年肺癌患者的治疗提供指导：（i）早期肺癌，（ii）局部晚期肺癌和（iii）转移性肺癌。我们还讨论了针对老年患者使用最新证据的情况。
